Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

BD Gets COVID-19 ‘Game-Changer’ Antigen Test Authorized By FDA

Executive Summary

As the US sees another massive spike in COVID-19 cases, public health officials are concerned that not enough testing is available. But the FDA’s EUA for BD’s antigen test could change the game, rapidly testing more of the population for the coronavirus.

You may also be interested in...



First Rapid COVID-19 Antigen Test Gets Green Light

In a potential game-changer in the ongoing fight to expand COVID-19 testing, the FDA has authorized a new kind of test that can be used by certain health care providers on-site to diagnose patients with the SARS-CoV-2 virus within minutes instead of days.

Digital Health Roundup: Digital Therapeutics, Restoring Function, Deals, Investing And Lobbying

In this roundup feature focusing on new developments in digital health, Medtech Insight spotlights the push behind digital therapeutics, Abbott’s biowearable line, Exec Chats with iRhythm and Cognetivity, Right To Repair rules for tech, and FDA's guidance on 3D-printing.

FDA To Convene Workshop On Using Ablation Therapy To Treat Certain Lung Cancers

The US regulatory agency will hold a two-day online workshop in April on how transbronchoscopic thermal ablation devices may be developed to treat intermediate-stage lung tumors known as oligometastases to the lung (OML).

Topics

Related Companies

UsernamePublicRestriction

Register

MT142384

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel